1 Reason Compass Pathways Is Worth a Second Look This Month
Key PointsFDA approval could provide a significant catalyst for shares.
Compass Pathways, a company developing a synthetic version of psilocybin for treating treatment-resistant depression, is on the verge of potentially receiving FDA approval for its treatment, COMP360. Recent positive results from two Phase 3 trials have bolstered investor confidence, and the FDA has granted COMP360 a Commissioner's National Priority Voucher, which could expedite the review process.
If approved, COMP360 could offer lasting relief with fewer treatments compared to conventional antidepressants. Analysts have set high expectations for the stock, with an average price target of $23.75, representing approximately 95% upside from its current trading price around $12. While approval is not guaranteed, the accelerated regulatory pathway and strong Phase 3 trial results suggest a potential significant boost in stock value for investors who buy now.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
